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Background: AIDS, caused by HIV, is a multisystem disease that affects hematopoiesis. The 
aim of this study was to assess cytopenias among HIV-infected children who had a follow-up 
at Felege Hiwot Referral Hospital, Bahir Dar, northwest Ethiopia.
Methods: An institution-based cross-sectional study was conducted between April and May 
2013. Systematic random sampling method was used to select the study participants. Descriptive 
statistics, independent t-test as well as chi-square and logistic regression were used for analysis. 
A p-value <0.05 was considered as statistically significant.
Results: A total of 224 children (112 highly active antiretroviral therapy [HAART]-naïve and 
112 HAART-experienced) participated in the study. The magnitude of anemia, thrombocytopenia, 
neutropenia, leukopenia and pancytopenia among HAART-naïve HIV-infected children were 
30.4%, 9.8%, 8%, 4.5% and 1.8%, respectively. The overall prevalence of anemia, neutropenia, 
thrombocytopenia, leukopenia and pancytopenia were 29.5%, 8.9%, 8%, 4.5% and 1.4%, respec-
tively. Cluster of differentiation-4 percentage and mean corpuscular volume were significantly 
different between HAART-experienced and HAART-naïve children. Being of younger age and 
severely immunosuppressed were risk factors of anemia.
Conclusion: Anemia was the most common cytopenia, followed by neutropenia. Severe immu-
nosuppression and younger age were significantly associated with anemia. Therefore, emphasis 
should be given for investigation and management of cytopenias in HIV-infected children, 
particularly for those who are immunosuppressed and of younger age.
Keywords: anemia, children, cytopenia, HAART, HIV, leukopenia, neutropenia, pancytopenia, 
thrombocytopenia
Background
AIDS is caused by HIV and is characterized by progressive damage to the body’s 
immune system, which results in a number of OIs, immunological and hematological 
complications.1,2 Immunological complication due to CD4+ T-lymphocyte depletion 
is a hallmark of HIV infection.3 Hematological manifestations are among the most 
common clinicopathological manifestations of HIV infection, and they have been 
documented as the second most common cause of morbidity and mortality in HIV 
patients.4–6 These complications are generally marked with cytopenias and dysplasias 
of all major blood cell lines, leading to anemia, leukopenia, thrombocytopenia and 
neoplasms.7–9
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Despite the attempts made to clearly understand the hema-
topoiesis impairment mechanism(s), it remained an intractable 
problem because of the paucity of studies using a suitable 
experimental animal model that closely replicates human 
hematopoiesis during an ongoing HIV infection in vivo.10 It 
has been evidenced that HIV-associated cytopenias seem to be 
dependent on the level of viral replication, OIs, liver cirrhosis, 
malignancies and the effects of the HAART used.11,12 Involve-
ment of the hematopoietic system tends to be more severe in 
advanced stages of the disease.7,13 The incidence and severity of 
cytopenias are generally correlated to the stage of the disease. 
In addition, cytopenias can adversely affect ART outcomes and 
result in higher mortality.12,14–16 In HIV-infected children, cyto-
penias are the common problems.3,17–21 The pathophysiology 
of HIV-related cytopenias in childhood is not well understood, 
which may be due to the complicated and dynamic changes 
associated with normal hematological development in early 
life.18 The frequency and severity of cytopenias vary, while 
the disease progresses from the asymptomatic carrier state 
to advanced symptomatic stages. The frequencies of anemia, 
leukopenia and thrombocytopenia in asymptomatic HIV-
infected children were 20%, 10% and 15%, respectively, while 
in HIV-infected children at the AIDS stage, their proportions 
were 70%, 65% and 40%, respectively.22
Even though the use of HAART reduces the rate of mor-
tality, therapy-related potential adverse events are becoming 
the major concern in the era of HAART, particularly in 
resource-limited counties where undernutrition is com-
mon.23–26 Both HIV/AIDS and undernutrition affect immune 
function; HIV/AIDS, together with lack of essential micro-
nutrients, leads to severe immune dysfunction. Furthermore, 
compromised immune status increases susceptibility to 
infectious diseases and profoundly complicates cytopenias 
and their management.27,28 A number of studies have been 
conducted on cytopenias among adult HIV-infected patients 
before and after the initiation of HAART. However, in HIV-
infected children, limited data are available, and these are 
not much well elucidated, especially in developing countries. 
Moreover, there are controversial reports regarding the effi-
cacy and impact of HAART in resolving immunological and 
hematological complication in HIV patients.29–31 Thus, this 
study was aimed to assess the cytopenias among HAART-
naïve and HAART-experienced HIV-infected children.
Patients and methods
Study setting, population, sample size and 
sampling procedure
A cross-sectional study was conducted at Bahir Dar Felege 
Hiwot Referral Hospital, northwest Ethiopia, between April 
and May 2013. Felege Hiwot Referral Hospital is found in 
Bahir Dar, which is located 565 km away from Addis Ababa. 
Geographically, the city is located between 9°20′ and 14°20′ 
north latitudes and between 30°20′ and 40°20′ east longitudes 
and is at an altitude of 1,830 m above sea level. The hospital 
serves >5 million people and provides comprehensive health 
care services, including ART treatment and monitoring for 
both pediatric and adult people living with HIV/AIDS.
The study population comprised HIV-infected children 
who had been followed up at the Pediatric ART Clinic of 
Felege Hiwot Referral Hospital during the study period. 
HIV-infected children who were HAART-naïve and HAART-
experienced for at least 6 months were eligible to be included 
in the study. Children who had been previously confirmed as 
having chronic renal failure and liver disease prior to HIV 
infection, as well as those who underwent radiation therapy 
and/or immunosuppressive chemotherapy in the previous 
45 days, were excluded from the study due to the fact that 
these may unambiguously affect the hematological values.
For sample size determination, double population pro-
portional formula was used by considering the following 
assumptions: 2-sided confidence level at 95%, power of 
80% and 1:1 ratio of HAART-experienced:HAART-naïve 
children. We used a 21.9% prevalence rate of anemia for 
HAART-experienced children, as per a study conducted in 
Jimma, Ethiopia,32 and 40% for HAART-naïve children (a 
default value of OpenEpi) to get the maximum sample size. 
Then, a total of 224 HIV-infected children (112 HAART-
naïve and 112 HAART-experienced for at least 6 months) 
were included in the study.
A systematic random sampling technique was used. On a 
daily basis, an average of 9 HAART-naïve and 12 HAART-
experienced children were getting health care service in the 
Pediatric ART Clinic of Felege Hiwot Referral Hospital. A 
total of 840 HIV-infected children (360 HAART-naïve and 
480 HAART-experienced) visited the ART clinic during the 
study period. Every third HAART-naïve HIV-infected child 
from the sequence of ART visitors was included in the study. 
Similarly, every fourth HAART-experienced HIV-infected 
child was included.
Data collection and laboratory analysis
Sociodemographic and socioeconomic characteristic of chil-
dren and their caregivers were collected using a structured 
questionnaire via a face-to-face interview technique. Clinical 
data were collected by reviewing the medical records of HIV-
infected children. The aforementioned data were collected by 
trained clinical nurses working in the Pediatric ART Clinic. 
Weight and height were measured, and the weight-for-age 
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status and height-for-age status were scored from the child’s 
growth monitoring chart.
Venous blood (4 mL) was collected from each study par-
ticipant using test tubes containing ethylenediaminetetraace-
tic acid following aseptic procedures. Part of the blood sample 
was analyzed using Cell DYN 1800 (Abbott Laboratories, 
Abbott Park, IL, USA) for the determination of hematological 
parameters, which include RBC parameters (RBC count, Hg 
level, MCH, MCHC, MCV and RDW%); WBC parameters 
(total WBC count, ANC, neutrophil percentage, lymphocyte 
count, lymphocyte percentage, mid count that encompasses 
eosinophil, basophil and monocyte and mid cell percentage) 
and platelet parameter (platelet count and MPV). The remain-
ing blood sample was analyzed for the determination of CD4+ 
T-cell value using fluorescence-activated cell sorter counter 
(BD, San Jose, CA, USA). While doing all laboratory analy-
ses, the standard operating procedure, daily maintenance, 
weekly maintenance and internal quality control procedure 
were strictly followed throughout the research process.
Assessment of cytopenias and 
immunological status
HIV-associated immunodeficiency was defined using the 
World Health Organization (WHO) age-related CD4 value 
stratification for HIV-infected infants and children.33 Mild 
immunodeficiency was defined as CD4% of 30% to <35% for 
infants <11 months, CD4% of 25% to <30% for children of 
age 12–35 months, CD4% of 20% to <25% for children aged 
36–59 months and CD4 count of 350–499 cells/mm3 for chil-
dren aged >5 years. Advanced immunodeficiency was defined 
as follows: CD4% of 25% to <30% for infants <11 months, 
CD4% of 20% to <25% for children aged 12–35 months, 
CD4% of 15% to <20% for children aged 36–59 months and 
CD4 count of 200–349 cells/mm3 for children aged >5 years. 
Severe immunodeficiency was also defined as follows: CD4% 
<25% for infants <11 months, 15% to <20% for children aged 
12−35 months and <15% for children aged >3 years.33
Anemia was defined based on the WHO criteria after 
Hg has been adjusted for altitude and was stratified based 
on age (Hg <11.0 g/dL for children aged 6–59 months, 
Hg <11.5 g/dL for children aged 5–11 years and Hg 
<12.0 g/dL for children aged ≥12 years). Mild anemia was 
defined as follows: Hg 10.0–10.9 g/dL for children aged 
5–59 months, 11.0–11.4 g/dL for children aged 5–11 years 
and 11.0–11.9 g/dL for children aged 12–14 years. Moderate 
anemia was defined as Hg 7.0–9.9 g/dL for children aged 
5–59 months and 8–10.9 g/dL for children aged 5–14 years. 
Severe anemia was also defined as Hg <7.0 g/dL for children 
aged 6–59 months and <8.0 g/dL for those aged 5–14 years.34
Leukopenia was defined as a total WBC count <3,000 cells/
mm3.9 Thrombocytopenia and thrombocytosis were defined as 
a platelet count <150,000/mm3 and platelet count >450 × 103 
cells/mm3, respectively.32 Neutropenia was also defined as 
absolute neutrophil count of <1,000/mm3, and the severity has 
also been classified as mild, moderate and severe.32
Statistical analysis
Data were cleaned, sorted, categorized, coded and entered 
into Epi Info version 3.5.1. The data were transferred to SPSS 
version 20 for analysis. Descriptive statistics were obtained 
and the results are presented in Tables 1–6 and Figure 1. Nor-
mality of data was checked; and chi-square and independent 
t-tests were used to compare the mean hematological values 
between the HAART-naïve and HAART-experienced HIV-
infected children. Bivariate logistic regression analyses were 
carried out for the cytopenias, and variables having p-value 
<0.2 in bivariate logistic analysis were included in the mul-
tivariable logistic analysis model to assess the association 
between cytopenias and explanatory variables. Odds ratios 
(ORs) with 95% CIs were used to measure the strength of 
the statistical associations. A p-value <0.05 was considered 
statistically significant.
Ethical considerations
This study was approved by the College of Medicine and 
Health Sciences Research Ethical Committee and the Insti-
tutional Review Board of the University of Gondar. The 
purpose and importance of the study was explained to each 
caregiver. Informed written consent was taken from the care-
givers, and in addition, assent was obtained from children 
aged >7 years before the commencement of the study. To 
ensure confidentiality of participants and their information, 
anonymous typing was used whereby the name of the par-
ticipants and any participants’ identifiers were not written on 
the questionnaire. The participants were interviewed alone 
to maintain their privacy. Laboratory findings of study par-
ticipants were communicated with the responsible clinicians 
assigned at the Pediatric ART Clinic.
Results
Sociodemographic characteristics
A total of 224 study participants were enrolled in this study. 
The median age of the study participant was 8 years (interquar-
tile range: 6 years). More than half of the study participants, 
126 (56.3%), were males. Among the study participants, 180 
(80.4%) were from urban setting and 96 (42.9%) were attend-
ing primary school. A majority, 157 (70.1%), of caregivers 
earned monthly income <1,400 ETB (Table 1).
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Medical characteristics of the study 
participants
Among the participants, 64 (57.2%) of HAART-naïve and 
47 (41.9%) of HAART-experienced children were in WHO 
clinical stage I. Thirty (26.8%) and 39 (34.8%) of HAART-
naïve children were underweight and stunted, respectively, 
whereas 44 (39.3%) and 31 (27.7%) HAART-experienced 
children were underweight and stunted, respectively. More-
over, 19 (17%), 16 (14.3%), 15 (13.4%), 15 (13.4%), 14 
(12.5%) and 9 (8%) of HAART-naïve children presented 
with fever, skin rash, diarrhea, OIs, pneumonia and oral 
thrush, respectively. Likewise, 14 (12.5%), 13 (11.6%), 10 
(9%), 10 (9%), 9 (8%) and 8 (7.1%) of HAART-experienced 
children presented with skin rash, fever, pneumonia, OIs, 
gastroenteritis and diarrhea, respectively. Severe, advanced 
and moderate immunosuppression was observed among 
17.9%, 12.9% and 32.1% of the study participants, respec-
tively (Table 2).
Cytopenias
Of the total study participants, 66 (29.5%), 20 (8.9%), 18 
(8%), 10 (4.5%) and 3 (1.4%) were anemic, neutropenic, 
thrombocytopenic, leukopenic and pancytopenic, respec-
tively. The occurrence of anemia, thrombocytopenia, neutro-
penia, leukopenia and pancytopenia among HAART-naïve 
HIV-infected children was reported to be 30.4% (n=34), 9.8% 
(n=11), 8% (n=9), 4.5% (n=5) and 1.8% (n=2), respectively 
(Figure 1).
Comparison of hematological profile
The mean values (±SD) of RBC, Hg, WBC, ANC, lympho-
cyte count, platelet count and absolute CD4 count in HAART-
naïve children were 4.48±0.58 × 106/µL, 13.25±3.03 g/dL, 
8.18±3.32 × 103/µL, 3.94±2.26 × 103/µL, 3.46±2.2 × 103/µL, 
297.91±107.67 × 103/µL and 873.16±446.57/µL respec-
tively. In children who were HAART-experienced, the mean 
values (±SD) were 4.94±4.75 × 106/µL, 13.21±1.6 g/dL, 
8.01±3.26 × 103/µL, 3.84±2.16 × 103/µL, 3.75±5.17 × 103/ µL, 
300.99±106.16 × 103/µL and 767.86±486.6/µL, respectively.
On the basis of the mean values, the data indicated that 
Hg, RBC count, WBC count and platelet count did not show 
statistically significant differences between HAART-naïve 
and HAART-experienced HIV-infected children. However, 
there was a statistically significant difference in CD4% and 
MCV values between HAART-naïve and HAART-experi-
enced children (p<0.05) (Table 3).
Table 1 Sociodemographic characteristics of caregivers/
guardians and HIV-infected children at the Pediatric ART Clinic, 
Felege Hiwot Referral Hospital, Bahir Dar, northwest Ethiopia, 
2013
Characteristics HAART-
naïve
HAART-
experienced
Total
n (%) n (%) N (%)
Age of child, years
≤5 32 (28.6) 24 (21.4) 56 (25)
6–10 53 (47.3) 53 (47.3) 106 (47.3)
11–14 27 (24.1) 35 (31.2) 62 (27.7)
Sex of child
Male 67 (59.8) 59 (52.7) 126 (56.3)
Female 45 (40.2) 53 (47.3) 98 (43.7)
Residence of child
Urban 89 (79.5) 91 (81.25) 180 (80.4)
Rural 23 (20.5) 21 (18.75) 44 (19.6)
Educational status of children
Nursery 15 (13.4) 9 (8) 24 (10.7)
Kindergarten 32 (28.6) 26 (23.2) 58 (25.9)
Primary school (1–4) 51 (45.5) 45 (40.2) 96 (42.9)
Elementary (5–8) 14 (12.5) 32 (28.6) 46 (20.5)
Whom the child lives with
Parents 72 (64.3) 71 (63.4) 143 (63.8)
Father only 7 (6.2) 15 (13.4) 22 (9.8)
Mother only 23 (20.5) 18 (16) 41 (18.3)
Grandparents 2 (1.8) 2 (1.8) 4 (1.8)
Guardian 1 (0.9) 1 (0.9) 2 (0.9)
Relative 5 (4.5) 3 (2.7) 8 (3.6)
Caregiver 2 (1.8) 2 (1.8) 4 (1.8)
Parental status
Both alive 73 (65.2) 77 (68.7) 150 (67)
Father dead 18 (16.1) 10 (8.9) 28 (12.5)
Mother dead 6 (5.3) 16 (14.3) 22 (9.8)
Separated 8 (7.1) 6 (5.4) 14 (6.2)
Both mother and father dead 7 (6.3) 3 (2.7) 10 (4.5)
Family size, n
≤3 52 (46.4)) 46 (41.1) 98 (43.8)
4–5 54 (48.2) 54 (48.2) 108 (48.2)
>5 6 (5.4) 12 (10.7) 18 (8)
Monthly family income, ETB
Lowest 75 (67) 82 (73.2) 157 (70.1)
Middle 36 (32.1) 27 (24.1) 63 (28.1)
High 1 (0.9) 3 (2.7) 4 (1.8)
Caregiver’s educational status
Unable to read and write  19 (17) 42 (37.5) 61 (27.2)
Able to read and write only 22 (19.6) 14 (12.5) 36 (16.1)
Primary school 18 (16.1) 16 (14.3) 34 (15.2)
High school 23 (20.5) 17 (15.2) 40 (17.9)
Tertiary education 30 (26.8) 23 (20.5) 53 (23.7)
Caregiver occupational status
Privately employed 43 (38.4) 44 (39.3) 87 (38.8)
Government employed 23 (20.5) 35 (31.2) 58 (25.9)
Merchant 26 (23.2) 16 (14.3) 42 (18.8)
Farmer 20 (17.9) 17 (15.2) 37 (16.5)
Abbreviations: ART, antiretroviral treatment; ETB, Ethiopian Birr; HAART, highly 
active antiretroviral therapy; HIV, human immunodeficiency virus.
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Table 2 Medical characteristics of HIV-infected children at the Pediatric ART Clinic, Felege Hiwot Referral Hospital, Bahir Dar, 
northwest Ethiopia, 2013 (N=224)
Clinical characteristic HAART-naïve HAART-experienced Total
n (%) n (%) N (%)
WHO staging
I 64 (57.2) 47 (41.9) 111 (49.6)
II 36 (32.1) 32 (28.6) 68 (30.3)
III 12 (10.7) 30 (26.8) 42 (18.8)
IV 0 3 (2.7) 3 (1.3)
Immune status
Severe immunosuppression 17 (15.2) 23 (20.5) 40 (17.9)
Advanced immunosuppression 12 (10.7) 17 (15.2) 29 (12.9)
Mild immunosuppression 40 (35.7) 32 (28.6) 72 (32.1)
Normal immune status 43 (38.4) 40 (37.7) 83 (37.1)
Weight-for-age status
Underweight 30 (26.8) 44 (39.3) 74 (33)
Normal 82 (73.2) 68 (60.7.) 150 (67)
Height-for-age status
Stunted 39 (34.8) 31 (27.7) 70 (31.3)
Normal 73 (65.2) 81 (72.3) 154 (68.7)
OIs
Yes 15 (13.4) 10 (9) 25 (11.2)
No 97 (86.6) 102 (91) 212 (88.8)
Gastroenteritis
Yes 6 (5.4) 9 (8) 15 (6.7)
No 106 (94.6) 103 (92) 209 (93.3)
Pneumonia
Yes 14 (12.5) 10 (9) 24 (10.7)
No 98 (87.5) 102 (91) 200 (89.3)
Oral thrush
Yes 9 (8) 5 (4.5) 14 (6.2)
No 103 (92) 107 (95.5) 210 (93.8)
Skin rash
Yes 16 (14.3) 14 (12.5) 30 (13.4)
No 96 (85.7) 98 (87.5) 194 (86.4)
Fever
Yes 19 (17) 13 (11.6) 32 (14.3)
No 93 (83) 99 (88.4) 192 (85.7)
Presence of diarrhea
Yes 15 (13.4) 8 (7.1) 23 (10.3)
No 97 (86.6) 104 (92.9) 201 (89.7)
Kind of diarrhea
Acute 8 (53.3) 7 (87.5) 15 (65.2)
Chronic 7 (46.7) 1 (12.5) 8 (34. 8)
Abbreviations: ART, antiretroviral treatment; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; OIs, opportunistic infections; WHO, 
World Health Organization.
Immune status and cytopenias
In this study, the prevalence of anemia among cases with severe, 
advanced and mild immunosuppression was 19 (47.5%), 5 
(17.2%) and 19 (26.4%), respectively. Furthermore, leukopenia 
and thrombocytopenia were found in 7 (17.5%) and 4 (10%) 
of cases with severe immune suppression (Table 4).
Comparison of cytopenias
The overall prevalence of anemia among HIV-infected children 
was 66 (29.5%). Anemia was found in 34 (30.5%) and 32 (28.6%) 
of HAART-naïve and HAART-experienced children, respectively. 
Among anemic cases, 1 (2.9%) of HAART-naïve and 2 (6.3%) 
of HAART-experienced children had severe anemia. About 11 
(9.8%), 9 (8%) and 5 (4.5%) of HAART-naïve HIV-infected 
children were thrombocytopenic, neutropenic and leukopenic, 
respectively. Moreover, 11 (9.8%), 7 (6.2%) and 5 (4.5%) of 
HAART-experienced HIV-infected children were neutropenic, 
thrombocytopenic and leukopenic, respectively (Table 5).
Anemia and associated factors
In bivariate analysis, age, severe immunosuppression and 
presence of bleeding were significantly associated with 
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anemia. But in multivariate logistic regression analysis, con-
trolling the possible cofounders, age of ≤5 years (adjusted 
odds ratio [AOR] =4.3, 95% CI: 1.7–10.9), age of 6–10 years 
(AOR =3.1, 95% CI: 1.3–7.2) and severe immunosuppres-
sion (AOR =2.95, 95%CI: 1.26–6.9) remained risk factors 
of anemia in HIV-infected children (Table 6).
Discussion
Cytopenia is the most common manifestation of advanced 
HIV infection.13,17,34 It is proposed that they are caused by 
the impaired growth and development of hematopoietic 
progenitor cells in the bone marrow due to the presence 
of HIV proteins and changes in the cytokine expression, 
which potentially lead to an altered maturation process and 
increased cell death of ≥1 bone marrow cell lineages.13,35 
These abnormalities have been directly correlated with the 
degree of immunosuppression and disease progression.15,36–38 
It has also been documented that they potentially limit the 
efficacy of HAART treatment and strongly predict morbidity 
and mortality in HIV-infected individuals.39–43
In this study, the prevalence of anemia was found to 
be 29.5%, making it more common than neutropenia, 
thrombocytopenia, leukopenia and cytopenia. This is in 
agreement with most of the literatures.9,32,44 Experimental 
studies suggest that dyserythropoiesis and early apoptosis of 
red cell precursors are common features in HIV infection.45 
In addition, HIV infection causes deficiency and defects in 
metabolism of iron, vitamin B12 and other micronutrients, 
which may lead to anemia.46,47 Moreover, immune suppres-
sion associated with HIV infection can be a cause for the 
onset of chronic inflammation and/or chronic disease, such 
Table 3 Comparison of hematological profiles between HAART-naïve and HAART-experienced HIV-infected children at Pediatric 
ART Clinic of Felege Hiwot Referral Hospital in Bahir Dar, northwest Ethiopia, 2013 (N=224)
Hematological values 
Variables HAART-naïve HAART-experienced Total p-value
Mean ± SD Mean ± SD Mean ± SD
Hg, g/dL 13.25±3.03 13.21±1.60 13.23±2.41 0.936
RBC, ×106/µL 4.48±0.58 4.94±4.75 4.71±3.39 0.319
HCT, % 38.21±4.85 38.43±4.00 38.32±4.44 0.708
MCV, fL 86.67±13.17 90.10±11.6 87.88±12.59 0.008**
MCH, pg 29.88±5.46 31.11±4.07 30.50±4.85 0.057
MCHC, g/dL 33.92±1.96 34.09±3.74 34.01±2.9 0.671
RDW, % 15.11±2.57 14.76±2.18 14.94±2.39 0.264
WBC, ×103/µL 8.18±3.32 8.01±3.26 8.09±3.29 0.708
ANC, ×103/µL 3.94±2.26 3.74±2.05 3.84±2.16 0.499
Lymphocyte count, ×103/µL 3.46±2.2 3.74±5.17 3.6±3.97 0.603
Mid (absolute), ×103/µL 1.34±1.7 2.21±8.10 1.76±5.77 0.247
Neutrophil, % 45.22±11.98 45.24±14 45.23±13.01 0.992
Lymphocyte, % 41.31±11.67 41.67±12.67 41.49±12.21 0.827
Mid, % 13.41±5.17 12.51±4.81 12.96±5 0.178
PLT, ×103cells/µL 297.91±107.67 300.99±105.10 299.45±06.16 0.829
MPV, % 9.72±1.92 9.82±7.96 9.77±5.77 0.899
CD4, cells/µL 873.16±466.53 767.86±486.60 820.51±78.52 0.100
CD4, % 28.73±14.22 24.78±10.69 26.73±12.71 0.018*
Note: *Significant at p<0.05; **significant at p<0.01 by independent t-test analysis.
Abbreviations: ANC, absolute neutrophil count; ART, antiretroviral treatment; CD4, cluster of differentiation-4; HAART, highly active antiretroviral therapy; HCT, 
hematocrit; HIV, human immunodeficiency virus; Hg, hemoglobin; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean 
corpuscular volume; mid, mixed cell; MPV, mean platelet volume; PLT, platelets; RBC, red blood cell; RDW, red cell distribution width; SD, standard deviation; WBC, white 
blood cell.
Table 4 Cytopenias with regard to immune status of HIV-
infected children at Pediatric ART Clinic, Felege Hiwot Referral 
Hospital, Bahir Dar, northwest Ethiopia, 2013 (N=224)
Cytopenic status Immunosuppression 
No (%) Mild (%) Advanced 
(%)
Severe 
(%)
Anemic status
Anemic 23 (27.7) 19 (26.4) 5 (17.2) 19 (47.5)
Nonanemic 60 (72.3) 53 (73.6) 24 (82.8) 21 (42.5)
Leukopenic status 
Leukopenic 7 (8.4) 3 (4.2) 0 0
Nonleukopenic 76 (91.6) 69 (95.8) 29 (100) 40 (100)
Neutropenic status
Neutropenic 10 (12) 9 (12.5) 0 1 (2.5)
Nonneutropenic 73 (88) 63 (87.5) 29 (100) 39 (97.5)
Thrombocytopenic status 
Thrombocytopenic 7 (8.4) 6 (8.3) 1 (3.4) 4 (10)
Nonthrombocytopenic 76 (91.6) 66 (91.7) 28 (96.6) 36 (90)
Abbreviations: ART, antiretroviral treatment; HIV, human immunodeficiency 
virus.
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Table 5 Cytopenias and other hematologic abnormalities in HIV-infected children with respect to HAART status at Pediatric ART 
Clinic, Felege Hiwot Referral Hospital, Bahir Dar, northwest Ethiopia, 2013 (N=224)
Variable HAART status Total (%) p-value 
HAART-
naïve (%)
HAART-
experienced (%) 
Anemic status 
Anemic 34 (30.4) 32 (28.6) 66 (29.5) 0.769
Nonanemic 78 (69.6) 80 (71.4) 158 (70.5) –
Severity of anemia 
Mild 16 (47.1) 21 (65.6) 37 (56.1) 0.315#
Moderate 17 (50) 9 (28.1) 26 (39.4) –
Severe 1 (2.9) 2 (6.3) 3 (4.5) –
RBC size 
Microcytic RBC 38 (33.9) 18 (16.1) 56 (25) 0.016
Normocytic RBC 61 (54.5) 76 (67.8) 137 (61.2) –
Macrocytic RBC 13 (11.6) 18 (16.1) 31 (13.8) –
RBC Hg content 
Hypochromic RBC 28 (25) 12 (10.7) 40 (17.1) –
Normochromic RBC 75 (70) 86 (75.8) 161 (71.9) 0.019
Hyperchromic RBC 9 (5) 14 (12.5) 23 (10.3) –
Leukopenic status 
Leukopenic 5 (4.5) 5 (4.5) 10 (4.5) 0.63
Nonleukopenic 107 (95.5) 107 (95.5) 214 (95.5) –
Neutropenic status 
Neutropenic 9 (8) 11 (9.8) 20 (8.9) 0.41
Nonneutropenic 103 (92) 101 (90.2) 104 (91.1) –
Severity of neutropenia 
Mild 8 (88.9) 9 (81.8) 17 (85) 0.579#
Moderate 1 (11.1) 2 (18.2) 3 (15) –
Thrombocytopenic status 
Thrombocytosis 8 (7.2) 6 (5.3) 14 (6.3) 0.506
Normal 93 (83.0) 99 (88.4) 192 (85.7) –
Thrombocytopenic 11 (9.8) 7 (6.3) 18 (8) –
Note: #Analysis done by Fisher’s exact test.
Abbreviations: ART, antiretroviral treatment; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; Hg, hemoglobin; RBC, red blood cell.
Table 6 Factors associated with anemia among HAART-naïve and HAART-experienced children at Pediatric ART Clinic, Felege Hiwot 
Referral Hospital, northwest Ethiopia, April–May 2013 (N=224)
Variable Anemic status Total (%) COR (95% CI) p-value AOR (95% CI) p-value 
Anemic (%) Nonanemic (%)
Age, years 
<5 24 (42.9) 32 (57.1) 56 (25) 4.42 (1.83–10.68) 0.001 4.3 (1.7–10.9) 0.002
6–10 33 (31.1) 73 (68.9) 106 (47.3) 2.66 (1.18–6.03) 0.019 3.1 (1.3–7.2) 0.011
11–14 9 (14.5) 53 (85.5) 62 (27.7) 1 – 1 –
Gastroenteritis
Yes 7 (53.8) 6 (46.2) 13 (5.9) 3.01 (0.97–9.32) 0.057 2.9 (0.3–1.05) 0.092
No 59 (28) 152 (72) 152 (94.1) 1 – 1 –
Bleeding 
Yes 3 (11.5) 23 (88.5) 26 (11.6) 0.28 (0.08–0.97) 0.044 0.3 (0.08–1.05) 0.059
No 63 (31.8) 135 (68.2) 198 (88.4) 1 – 1 –
Immunological status 
Severe immunosuppression 19 (47.5) 21 (52.5) 40 (17.9) 2.36 (1.08–5.2) 0.032 2.95 (1.26–6.9) 0.041
Advanced immunosuppression 5 (17.5) 24 (82.8) 29 (12.9) 0.54 (0.0.2–1.6) 0.27 0.67 (0.22–2.06) 0.48
Mild immunosuppression 19 (26.4) 53 (73.6) 72 (32.1) 0.94 (0.5–1.9) 0.85 1.25 (0.59–2.66) 0.55
No immunosuppression 23 (27.7) 60 (72.3) 83 (37.1) 1 – 1 –
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; COR, crude odds ratio; HAART, highly active antiretroviral therapy.
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as tuberculosis, recurrent diarrheal diseases, recurrent bac-
terial pneumonia and viral infections, which can result in 
anemia as well as other cytopenias. The prevalence of anemia 
(29.5%) is lower than that reported in Lagos (77.9%),9 Nepal 
(74.4%),48 West Bengal, India (69%),37 Uganda (57.6%)49 
and Dar es Salaam, Tanzania (44%),18 and it is higher than 
that in Addis Ababa, Ethiopia (22.2%),50 Jimma, Ethiopia 
(21.9%),32 Gondar, Ethiopia (16.2%)51 and Enugu, Nigeria 
(3%).52 This variation might be attributed to the differences 
in ethnicity, study designs and time of study. In addition, 
variation in age of the study participants, HAART status 
and cutoff value in defining anemia, local prevalence of 
parasitic infections such as malaria or hookworms, as well 
as local nutritional patterns might contribute to the variation 
in magnitude of anemia.
In this study, the number of cases with mild, moderate 
and severe anemia was 37 (56.1%), 26 (39.4%) and 3 (4.5%), 
respectively. This is comparable with the results of another 
study done in Gondar, Ethiopia,51 where occurrence of 
mild, moderate and severe anemia was 60.5%, 37.2% and 
2.3%, respectively. Similarly, it is in agreement with a study 
done in Addis Ababa, Ethiopia,50 where mild, moderate and 
severe anemia were reported to be 52.2%, 42.5% and 5%, 
respectively. The proportion of severe anemia in our studies 
is lower than that in studies conducted in Jimma, Ethiopia,32 
and Dar es Salaam, Tanzania,18 which were reported to be 
14.3% and 15%, respectively. The low magnitude of severe 
anemia in the current study might be related to the improved 
level of societal awareness about the positive implication 
of HIV monitoring and treatment, improved access to HIV 
monitoring and treatment facilities as well as updating of HIV 
monitoring and therapeutic modalities over time.
In the current study, the second most common cytopenia 
was neutropenia, which was observed in 8.9% HIV-infected 
children. The possible explanation may be the fact that HIV 
directly infects bone marrow and bone marrow stromal cell, 
which may reduce hematopoiesis. In addition, it is speculated 
that the decline in vitamin B12 and the presence of antibod-
ies to HIV envelope glycoprotein 120 suppress bone marrow 
progenitor cells, in addition to being implicated as a causal 
factor of cytopenia, including neutropenia.20 Furthermore, 
ART used to suppress the viral load may adversely affect the 
hematopoietic capacity of bone marrow.12 Compared to stud-
ies done in Lagos, Nigeria, (17.5%)9 and West Bengal, India 
(19%),37 the prevalence of neutropenia is lower. The possible 
difference might be the difference in immunological status 
of the study participants and sample size. In the study from 
Lagos, Nigeria, of the total 68 children who participated in 
the study, about 75% were in the Centers for Disease Con-
trol and Prevention, USA (CDC) clinical stages B and C. 
Likewise, in the West Bengal study, of the total 100 children 
participating in the study, 50% were in WHO stages 3 and 4. 
But, in the current study, 20% of the study participants were 
in WHO stages 3 and 4.
In this study, thrombocytopenia was found to be 8%, which 
is the third most common cytopenia in HIV-infected children. 
The possible biological explanations for why thrombocytope-
nia is common in HIV infection might be due to an increased 
platelet destruction either caused by the nonspecific deposition 
of circulating immune complexes on platelets or the presence 
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Figure 1 Frequency of cytopenias in HIV-infected children at Pediatric ART Clinic, Felege Hiwot Referral Hospital, Bahir Dar, northwest Ethiopia.
Abbreviations: ART, antiretroviral treatment; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus.
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of specific antiplatelet glycoprotein antibodies, leading to 
immune-mediated thrombocytopenia, as well as direct HIV 
infection of megakaryocytes and their precursors, resulting 
in higher thrombocytopenia15,53 The result is comparable to 
studies done in Mumbai, India (10%)54 and West Bengal, India 
(11%).37 However, it is higher than that in the report from Lagos 
(2.5%);9 and lower than studies done in Nepal (17.9%),48 Kenya 
(21%)44 and Uttar Pradesh, India (29.78%).55 The variations in 
prevalence could be attributed to the difference in the reference 
range used to define thrombocytopenia as Adetifa et al9 used 
platelet count <100 × 103/mm3; HAART status, as Kibaru et 
al44 included children who were HAART-naïve; and sample 
size, as Poudel et al48 and Kumar et al55 used small sample size 
to determine the magnitude of thrombocytopenia.
In the current study, 4.5% of study participants were 
leukopenic. This is comparable with a study done in Lagos, 
Nigeria (6%).9 However, it is lower than that in studies done 
at Kenyatta hospital, Kenya (10%)44 and West Bengal, India 
(34%),37 and higher than that in the study done in Mumbai, 
India (2%).54 The possible reason for the variation in magni-
tude of leukopenia might be due to the differences in ethnicity, 
age of study participants included in study, HAART status as 
well as prevalence of infectious and noninfectious diseases.
In this study, severe immunosuppression (AOR =2.95, 
95% CI: 1.26–6.9) was significantly associated with anemia. 
Similar findings had been reported previously in Addis Ababa, 
Ethiopia,50 Western Uganda,49 and South India,46 revealing that 
there was statistically significant association between immune 
suppression and anemia. This could be explained by the fact 
that immune suppression potentially leads to viral replication, 
which may cause anemia through increased cytokine-mediated 
myelosuppression and higher burden of OIs.13,56 Furthermore, 
age <5 years (AOR =4.3, 95% CI: 1.7–10.9) and age of 
6–10 years (AOR =3.1, 95% CI: 1.3–7.2) also remained risk 
factors of anemia. This is also similar with other studies.18,49,57 
The possible reason for increased risk of anemia in younger 
children may be related with the high nutritional requirement 
for production of RBCs and the high frequency of comorbid-
ity because their immune status is not well developed. Unlike 
anemia, neutropenia, thrombocytopenia and leukopenia were 
not significantly associated with independent variables. The 
possible explanation could be the small number of cases of 
children who had these cytopenias and the small sample size; 
therefore, the number of observations in each category of 
independent variables would be small and these observations 
would have low power to predict association.
In the current study, the mean MCV value in HAART-
experienced HIV-infected children was significantly higher 
than in children who were HAART naïve. The possible reason 
for the high MCV value in HAART-experienced HIV-infected 
children might be related with the use of zidovudine-based 
first-line HAART. In this study, of the total 18 children who 
were on first-line HAART having MCV value >100 fL, 11 
(61%) were taking zidovudine-based ART regimen. Evidence 
suggests that zidovudine causes marrow erythroid hypoplasia, 
aplasia and megaloblastic maturation, which can be accom-
panied by a progressive raise in erythrocyte MCV.58,59 The 
other possible reason for the difference would be related to the 
nutritional  deficiencies, particularly iron deficiency, the most 
common nutritional deficiency in developing countries,60 
which causes microcytic–hypochromic RBC morphology 
in HAART-naïve children.
The MCV could show an increment due to iron supple-
ments and nutritional modification provided after HAART 
initiation. Together with the macrocytosis that appears to 
be overt after they are initiated into zidovudine-containing 
regimens, the MCV value shows significant elevation. Our 
data also supported that microcytosis is significantly higher 
in HAART-naïve (33.9%), compared to HAART-experienced, 
HIV-infected children (16.1%). A retrospective study done in 
Kenya has shown that, compared with the baseline value, the 
mean MCV value of HIV-infected children was significantly 
raised at 6 months after initiation of HAART.61
However, the mean CD4% of HAART-experienced 
HIV-infected children was significantly lower than that of 
HAART-naïve ones. The possible reason for the low value 
of mean CD4% in HAART-experienced children might be 
delayed diagnosis and ART initiation, poor adherence to ART 
and delayed response to ART. These may limit the success of 
HAART and may be related with continued viral replication 
and immunological failure. Evidence also demonstrated that 
initiation of HAART in children with a low CD4 value is 
less likely to result in a robust increase in CD4 cells, thereby 
being less likely to achieve a successful treatment outcome.62 
Moreover, poor adherence to ART in children is one of the 
challenges in resource-limited settings, including Ethiopia.63–65
Limitations
The main limitation of this study is the cross-sectional nature 
of its design, which makes relationships between cytopenias 
and associated factors difficult, as it is temporal association. 
In addition, we were unable to analyze serum ferritin, vitamin 
B12 and folate levels and unable to perform bone marrow 
examination, which potentially limit this study. Another 
limitation of this study is that we did not assess all modifiable 
risk factors, such as intestinal parasitic infection, malaria, 
viral infections and fungal infections, which could potentially 
influence the magnitude and severity of  cytopenias. We did 
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not include HIV-negative children as a control to compare 
the magnitude of cytopenias between HIV-infected and 
noninfected children. Furthermore, the study is a single-
center institutional study that could not be generalized for 
HIV-infected children in the study area.
Conclusion
The prevalence of anemia was higher, meeting the WHO 
criteria for a moderate public health problem. Neutropenia 
was the second most common cytopenia among HIV-infected 
children in the study area. Severe immunosuppression and 
younger age were significantly associated with anemia. 
Moreover, the proportion of cytopenias did not significantly 
vary between HAART-naïve and HAART-experienced HIV-
infected children. Therefore, emphasis should be given for 
investigation and management of hematological abnormalities 
in HIV-infected children, particularly those who are immuno-
suppressed and of younger age. Furthermore, multicentered 
prospective studies need to be conducted to explore modifiable 
associated factors of cytopenias, patterns of cytopenias over 
time, and the impact of HAART on cytopenia among HIV-
infected children in resource-limited settings such as Ethiopia.
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